Literature DB >> 30739101

Growth Disturbances in Childhood Cancer Survivors.

Zoltan Antal1,2, Sadana Balachandar3.   

Abstract

Survival from childhood cancer has improved dramatically over the last few decades, resulting in an increased need to address the long-term follow-up and care of childhood cancer survivors. Appropriate linear growth is an important measure of health, with alterations of growth in children and short adult height in those who have completed growth serving as potential indicators of the sequelae of the underlying diagnosis or the cancer treatments. It is therefore critical that clinicians, particularly endocrinologists, be familiar with the patterns of altered growth which may be seen following diagnosis and treatment for childhood cancer. In this article, we will review the growth alterations seen in childhood cancer survivors, focusing on risk factors and considerations in evaluation and care.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Cancer; Childhood; Growth in children; Short stature

Mesh:

Year:  2019        PMID: 30739101     DOI: 10.1159/000496354

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  2 in total

1.  Prevalence of osteopathologies in a single center cohort of survivors of childhood primary brain tumor.

Authors:  Michael M Schündeln; Sebastian Fritzemeier; Sarah C Goretzki; Pia K Hauffa; Martin Munteanu; Cordula Kiewert; Berthold P Hauffa; Gudrun Fleischhack; Stephan Tippelt; Corinna Grasemann
Journal:  Front Pediatr       Date:  2022-07-18       Impact factor: 3.569

2.  Pre- and postdiagnosis growth failure, adult short stature, and untreated growth hormone deficiency in radiotherapy-treated long-term survivors of childhood brain tumor.

Authors:  Julia Anttonen; Tiina Remes; Pekka Arikoski; Päivi Lähteenmäki; Mikko Arola; Arja Harila-Saari; Tuula Lönnqvist; Tytti Pokka; Pekka Riikonen; Kirsti Sirkiä; Heikki Rantala; Marja Ojaniemi
Journal:  PLoS One       Date:  2022-09-06       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.